

David Charles

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7758074/publications.pdf>

Version: 2024-02-01

29
papers

623
citations

687363

13
h-index

610901

24
g-index

32
all docs

32
docs citations

32
times ranked

661
citing authors

#	ARTICLE	IF	CITATIONS
1	Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 731-737.	2.2	112
2	Deep brain stimulation in early-stage Parkinson disease. <i>Neurology</i> , 2020, 95, e393-e401.	1.1	75
3	Poststroke Spasticity: Predictors of Early Development and Considerations for Therapeutic Intervention. <i>PM and R</i> , 2015, 7, 60-67.	1.6	73
4	Primary results from the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE). <i>Journal of the Neurological Sciences</i> , 2015, 349, 84-93.	0.6	67
5	Effects of deep brain stimulation on rest tremor progression in early stage Parkinson disease. <i>Neurology</i> , 2018, 91, e463-e471.	1.1	55
6	Impact of Tremor on Patients With Early Stage Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 628.	2.4	30
7	Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins. <i>Toxins</i> , 2020, 12, 269.	3.4	29
8	Neuropsychological Effects of Deep Brain Stimulation in Subjects with Early Stage Parkinson's Disease in a Randomized Clinical Trial. <i>Journal of Parkinson's Disease</i> , 2015, 5, 151-163.	2.8	25
9	How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study. <i>Journal of Neurology</i> , 2019, 266, 3038-3046.	3.6	21
10	Pilot Study Assessing the Feasibility of Applying Bilateral Subthalamic Nucleus Deep Brain Stimulation in Very Early Stage Parkinson's Disease: Study Design and Rationale. <i>Journal of Parkinson's Disease</i> , 2012, 2, 215-223.	2.8	18
11	Teleneurology service provided via tablet technology: 3-year outcomes and physician satisfaction. <i>Rural and Remote Health</i> , 2019, 19, 4743.	0.5	18
12	Methods for Surgical Targeting of the STN in Early-Stage Parkinson's Disease. <i>Frontiers in Neurology</i> , 2014, 5, 25.	2.4	17
13	INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin. <i>Journal of Neurology</i> , 2018, 265, 402-409.	3.6	15
14	Cumulative effects of long-term treatment with abobotulinumtoxinA in cervical dystonia: Findings from a prospective, observational study. <i>Journal of the Neurological Sciences</i> , 2020, 416, 117015.	0.6	11
15	Patient Perspectives on Deep Brain Stimulation Clinical Research in Early Stage Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 89-94.	2.8	10
16	Vanderbilt University Medical Center Ambulatory Teleneurology COVID-19 Experience. <i>Telemedicine Journal and E-Health</i> , 2021, 27, 701-705.	2.8	10
17	Prevalence of Spasticity in Nursing Home Residents. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1157-1160.	2.5	8
18	Recruitment and Retention in Clinical Trials of Deep Brain Stimulation in Early-Stage Parkinson's Disease: Past Experiences and Future Considerations. <i>Journal of Parkinson's Disease</i> , 2018, 8, 421-428.	2.8	6

#	ARTICLE	IF	CITATIONS
19	The Role of Biosimilars in Patient Access to Therapeutic Antibodies for Immune Mediated Inflammatory Diseases. <i>Current Pharmaceutical Design</i> , 2018, 23, 6779-6783.	1.9	6
20	Early subthalamic nucleus deep brain stimulation in Parkinson's disease reduces long-term medication costs. <i>Clinical Neurology and Neurosurgery</i> , 2021, 210, 106976.	1.4	6
21	Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson's Disease Is Not Associated with Increased Body Mass Index. <i>Parkinson's Disease</i> , 2017, 2017, 1-4.	1.1	4
22	A Simple Bedside Screening Tool for Spasticity Referral. <i>Clinical Interventions in Aging</i> , 2020, Volume 15, 655-662.	2.9	4
23	The Minimum Data Set: An Opportunity to Improve Spasticity Screening. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 608-612.	2.5	1
24	Exploring the presence of multiple abnormal non-motor features in patients with cervical dystonia. <i>Journal of Clinical Neuroscience</i> , 2021, 94, 315-320.	1.5	1
25	Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study. <i>Clinical Parkinsonism & Related Disorders</i> , 2022, 6, 100142.	0.9	1
26	Poster 102: CD-PROBE (Cervical Dystonia Patient Registry for Observation of Botox Efficacy) A Multicenter, Observational Study of OnabotulinumtoxinA Injections in Cervical Dystonia (CD) Patients Baseline Data and Interim Patient Reported Outcome. <i>PM and R</i> , 2010, 2, S50.	1.6	0
27	Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE): Baseline Demographic and Clinical Characteristics. <i>PM and R</i> , 2013, 5, S148-S148.	1.6	0
28	Long-Term Care Resident Awareness and Interest in Spasticity Treatments. <i>Geriatrics (Switzerland)</i> , 2021, 6, 21.	1.7	0
29	Enhancing Performance of a Spasticity Screening Tool Using the Minimum Data Set. <i>Journal of the American Medical Directors Association</i> , 2021, , .	2.5	0